A contemporary analysis of parenteral nutrition-associated liver disease in surgical infants

J Pediatr Surg. 2011 Oct;46(10):1913-7. doi: 10.1016/j.jpedsurg.2011.06.002.

Abstract

Background/purpose: Despite advances in pediatric nutritional support and a renewed focus on management of intestinal failure, there are limited recent data regarding the risk of parenteral nutrition (PN)-associated liver disease in surgical infants. This study investigated the incidence of cholestasis from PN and risk factors for its development in this population.

Methods: A retrospective review was performed of all neonates in our institution who underwent abdominal surgery and required postoperative PN from 2001 to 2006. Cholestasis was defined as 2 conjugated bilirubin levels greater than 2 mg/dL over 14 days. Nonparametric univariate analyses and multivariate logistic regression were used to model the likelihood of developing cholestasis. Median values with range are presented.

Results: One hundred seventy-six infants met inclusion criteria, and patients received PN for 28 days (range, 2-256 days). The incidence of cholestasis was 24%. Cholestatic infants were born at an earlier gestational age (34 vs 36 weeks; P < .01), required a 3-fold longer PN duration (76 vs 21 days; P < .001), had longer inpatient stays (86 vs 29 days; P < .001), and were more likely to be discharged on PN. The median time to cholestasis was 23 days. Cholestasis was an early development; 77% of cholestatic infants developed cholestasis by 5 weeks of PN exposure. On multivariate regression, only prematurity was significantly associated with development of cholestasis (P < .05).

Conclusion: In this analysis, the development of PN-associated liver disease occurred early in the course of exposure to PN. These data help to define the time course and prognosis for PN-associated cholestasis in surgical infants.

MeSH terms

  • Cholestasis / drug therapy
  • Cholestasis / epidemiology
  • Cholestasis / etiology*
  • Diagnosis-Related Groups
  • Female
  • Humans
  • Hyperbilirubinemia / drug therapy
  • Hyperbilirubinemia / epidemiology
  • Hyperbilirubinemia / etiology*
  • Incidence
  • Infant, Newborn
  • Infant, Newborn, Diseases / surgery*
  • Infant, Premature, Diseases / surgery*
  • Logistic Models
  • Male
  • Nutritional Support
  • Parenteral Nutrition / adverse effects*
  • Postoperative Complications / etiology*
  • Postoperative Complications / mortality
  • Prognosis
  • Retrospective Studies
  • Ursodeoxycholic Acid / therapeutic use

Substances

  • Ursodeoxycholic Acid